Title:Optimization of Microemulsion Based Transdermal Gel of Triamcinolone
Volume: 12
Issue: 1
Author(s): Swati Jagdale*Bhagyashree Chaudhari
Affiliation:
- Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, MIT Campus, Pune, (MS), 411038,India
Keywords:
Triamcinolone, transdermal, microemulsion, gel, delivery, optimizatio
Abstract: Background: Triamcinolone is a long acting corticosteroid used in the treatment
of arthritis, eczema, psoriasis and similar conditions which cause inflammation. Triamcinolone
has half-life of 88min. Prolonged oral use is associated with gastrointestinal adverse
effects as peptic ulcer, abdominal distention and ulcerative esophagitis as described in various
patents. Microemulgel offers advantage of better stability, better loading capacity and
controlled release especially for drug with short half life.
Objective: Objective of the present study was to optimize microemulgel based transdermal
delivery of triamcinolone.
Method: Saturated solubility of triamcinolone in various oils, surfactants and co-surfactants
is estimated. Pseudo-ternary phase diagrams were constructed to determine the region of
transparent microemulsion. Microemulsion was evaluated for globule size (FE-SEM, zetasizer),
% transmittance, pH, viscosity, conductivity etc. Design of experiment was used to
optimize microemulsion based gel. Carbopol 971P and HPMC K100M were used as independent
variables. Microemulsion based gel was evaluated for in-vitro as well as ex-vivo
parameters.
Results: Microemulsion was formulated with oleic acid, lauroglycol FCC and propylene
glycol. PDI 0.197 indicated microemulsion is mono-disperse. 32 factorial design gave batch
F8 as optimized. Design expert suggested drug release; gel viscosity and bio-adhesive
strength were three significant dependant factors affecting the transdermal delivery. F8
showed drug release 92.62.16±1.22% through egg membrane, 95.23±1.44% through goat
skin after 8hr and Korsmeyer-Peppas release model was followed.
Conclusion: It can be concluded that a stable, effective controlled release transdermal microemulgel
was optimised for triamcinolone. This would be a promising tool to deliver
triamcinolone with enhanced bioavailability and reduced dosing frequency.
